The clinical paradigm surrounding polyendocrine metabolic ovarian syndrome has evolved dramatically in recent years. Historically viewed through a narrow gynaecological lens, clinicians now recognize this condition as a complex, lifelong metabolic disorder. Consequently, modern clinical strategies emphasize comprehensive cardiometabolic surveillance alongside reproductive care.

Nomenclature Shift to Polyendocrine Metabolic Ovarian Syndrome

Medical experts officially introduced the PMOS nomenclature in 2026 to address critical historical misconceptions. Previously, the term polycystic ovary syndrome incorrectly suggested that ovarian cysts were the primary driver of pathology. However, ovarian morphology represents only one variable manifestation of a much broader systemic disorder. Therefore, the revised terminology accurately reflects the multifaceted endocrine, metabolic, and reproductive derangements observed in clinical practice. Furthermore, this transition reduces diagnostic ambiguity and eliminates unwarranted stigma for patients. As a result, primary care physicians and specialists can adopt a more holistic diagnostic framework across different age groups.

Epidemiological Insights and Global Disease Burden

Global epidemiological surveys confirm that PMOS impacts approximately 10% to 13% of women of reproductive age. However, recent systematic analyses reveal substantial regional variations in prevalence and phenotypic expression. For example, South Asian populations demonstrate distinct vulnerability, frequently presenting with pronounced metabolic derangements at younger ages and lower body mass thresholds. In addition, large population-based cohort studies indicate that standard clinical registries significantly underestimate true community burden. Consequently, widespread underdiagnosis delays timely clinical intervention. Clinicians must therefore maintain heightened vigilance during routine health encounters to detect early endocrine dysfunction.

Pathophysiology of Insulin Resistance and Hyperinsulinaemia

Insulin resistance represents the central pathophysiological cornerstone linking endocrine imbalance with systemic metabolic dysfunction. Specifically, tissue-level insulin resistance affects nearly 75% of lean women and over 95% of overweight individuals with PMOS. Consequently, compensatory hyperinsulinaemia stimulates ovarian theca cells to produce excessive androgens while concurrently suppressing hepatic sex hormone-binding globulin synthesis. Moreover, hyperinsulinaemia directly impairs follicular maturation and disrupts ovulatory cycles. Cellular lipotoxicity and persistent low-grade inflammation further amplify peripheral insulin receptor defects. Thus, targeted metabolic therapies directly improve both hormonal equilibrium and ovulatory competence.

Metabolic Complications and Type 2 Diabetes Vulnerability

Extensive population data demonstrate that patients face an almost threefold elevated risk of developing type 2 diabetes (odds ratio 2.9). Furthermore, metabolic syndrome, dyslipidaemia, and metabolic dysfunction-associated steatotic liver disease manifest frequently in affected cohorts. Notably, these metabolic derangements emerge independently of baseline body mass index, although coexisting adiposity severely exacerbates overall risk. Therefore, clinical guidelines mandate routine metabolic screening, including baseline fasting lipid profiles and oral glucose tolerance testing. Additionally, clinicians should repeat glycaemic assessments every one to three years based on individual cardiometabolic risk stratification.

Long-Term Cardiovascular Trajectories and Risk Stratification

Contemporary longitudinal studies demonstrate an alarming rise in major adverse cardiovascular events among individuals with PMOS, reporting hazard ratios between 1.2 and 2.5. Notably, cardiovascular risk profiles begin to diverge significantly from unaffected peers around 35 years of age. Accelerated coronary artery calcification, persistent endothelial dysfunction, and early-onset arterial stiffness drive these adverse clinical trajectories. Consequently, clinicians must not overlook cardiovascular risk in young, asymptomatic women. Early stratification enables timely implementation of lifestyle modifications, blood pressure control, and targeted lipid-lowering pharmacotherapy.

Integrated Diagnostic and Patient-Centred Management Approaches

Optimal care demands an integrated, multidisciplinary management model spanning reproductive, metabolic, and psychological domains. Specifically, lifestyle modification remains the foundational first-line intervention, improving insulin sensitivity, lipid parameters, and menstrual cyclicity. Additionally, insulin-sensitizing agents, particularly metformin and modern incretin-based therapies, demonstrate substantial clinical utility for metabolic protection. Furthermore, clinicians must proactively address associated anxiety, depression, and obstructive sleep apnoea. In summary, identifying PMOS as an early-life harbinger of cardiometabolic disease empowers clinicians to deliver individualized, lifelong preventive care.

What prompted the renaming of PCOS to polyendocrine metabolic ovarian syndrome?

The revised terminology clarifies that the condition is a systemic endocrine and metabolic disorder rather than a localized ovarian disease. Historically, the misnomer implied pathological ovarian cysts, creating diagnostic confusion and fragmented care. The updated name accurately captures lifelong systemic features, including hyperandrogenism, insulin resistance, and heightened cardiometabolic risk across the lifespan.

How does insulin resistance accelerate cardiovascular risk in PMOS?

Insulin resistance triggers compensatory hyperinsulinaemia, which promotes atherogenic dyslipidaemia, chronic low-grade vascular inflammation, and endothelial dysfunction. Additionally, hyperinsulinaemia drives excessive ovarian androgen secretion and neuroendocrine dysregulation. Together, these interrelated factors accelerate vascular stiffness and premature subclinical atherosclerosis, significantly elevating the lifetime risk of coronary heart disease and stroke.

Which cardiometabolic screening tests should clinicians prioritize for patients?

Clinicians should perform a comprehensive baseline evaluation including a 75-gram two-hour oral glucose tolerance test, fasting lipid panel, blood pressure measurement, and body mass index assessment. Furthermore, high-risk individuals require repeat glycaemic screening every one to three years, alongside continuous monitoring for metabolic dysfunction-associated liver disease and obstructive sleep apnoea.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Forslund M et al. Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk. J Intern Med. 2026 Aug 30. doi: 10.1111/joim.70156. PMID: 42669621.
2. Teede HJ et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43-G64.
3. Global PMOS Nomenclature Consensus Consortium. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet Diabetes Endocrinol. 2026;14(6):412-425.